Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study

John W.C. Chang, Ming Mo Hou, Jia Juan Hsieh, Yun Chung Cheung, Hung Ming Wang, Jen Shi Chen, Cheng Hsu Wang, Chih Hung Chen, Kun Yun Yeh, Li Ying Ou, Chia Hsun Hsieh, Hong Dar Isaac Wu, Ying Tsong Chen, Il Chi Chang, Shiu Feng Huang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The time schedules for response evaluation of epidermal growth factor receptor-tyrosine kinase Inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are still ill-defined. Methods: Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Eligible patients were treated with either 250 mg of gefitinib or 150 mg of erlotinib once daily. The early response rate [computed tomography (CT) scan on Day 14], definitive response rate determined on Day 56, progression-free survival (PFS), overall survival (OS), and toxicity profile were assessed prospectively. Results: Thirty-nine patients were enrolled in this study. A total of 29 patients (29/39, 74.4%) achieved partial response (PR). Twenty-one patients (21/39, 53.8%) had early radiological response on Day 14. The early radiological response rate in patients with PR was 72.4% (21/29). Only eight patients without a PR on early CT still ended with PR. Among the 29 patients with PR, the PFS (8.1 months) and OS (18.3 months) of the 21 patients with early CT response were shorter than those of the 8 patients without early CT response (11.9 and 24.0 months for PFS and OS, respectively). But the survival differences were statistically non-significant. Conclusions: A very high percentage (72.4%, 21/29) of NSCLC patients with EGFR mutations with PR demonstrates early radiological response to EGFR-TKIs, which would advocate early radiological examination for EGFR-TKI therapy in NSCLC patients.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalBiomedical Journal
Volume38
Issue number3
DOIs
Publication statusPublished - May 1 2015
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Prospective Studies
Mutation
Tomography
Disease-Free Survival
Survival
Appointments and Schedules

Keywords

  • computed tomography scan
  • epidermal growth factor receptor
  • non-small cell lung cancer
  • treatment response
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations : A prospective study. / Chang, John W.C.; Hou, Ming Mo; Hsieh, Jia Juan; Cheung, Yun Chung; Wang, Hung Ming; Chen, Jen Shi; Wang, Cheng Hsu; Chen, Chih Hung; Yeh, Kun Yun; Ou, Li Ying; Hsieh, Chia Hsun; Wu, Hong Dar Isaac; Chen, Ying Tsong; Chang, Il Chi; Huang, Shiu Feng.

In: Biomedical Journal, Vol. 38, No. 3, 01.05.2015, p. 221-228.

Research output: Contribution to journalArticle

Chang, JWC, Hou, MM, Hsieh, JJ, Cheung, YC, Wang, HM, Chen, JS, Wang, CH, Chen, CH, Yeh, KY, Ou, LY, Hsieh, CH, Wu, HDI, Chen, YT, Chang, IC & Huang, SF 2015, 'Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study', Biomedical Journal, vol. 38, no. 3, pp. 221-228. https://doi.org/10.4103/2319-4170.138320
Chang, John W.C. ; Hou, Ming Mo ; Hsieh, Jia Juan ; Cheung, Yun Chung ; Wang, Hung Ming ; Chen, Jen Shi ; Wang, Cheng Hsu ; Chen, Chih Hung ; Yeh, Kun Yun ; Ou, Li Ying ; Hsieh, Chia Hsun ; Wu, Hong Dar Isaac ; Chen, Ying Tsong ; Chang, Il Chi ; Huang, Shiu Feng. / Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations : A prospective study. In: Biomedical Journal. 2015 ; Vol. 38, No. 3. pp. 221-228.
@article{39d181bc304445aa8313b828aa0b6bb1,
title = "Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study",
abstract = "Background: The time schedules for response evaluation of epidermal growth factor receptor-tyrosine kinase Inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are still ill-defined. Methods: Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Eligible patients were treated with either 250 mg of gefitinib or 150 mg of erlotinib once daily. The early response rate [computed tomography (CT) scan on Day 14], definitive response rate determined on Day 56, progression-free survival (PFS), overall survival (OS), and toxicity profile were assessed prospectively. Results: Thirty-nine patients were enrolled in this study. A total of 29 patients (29/39, 74.4{\%}) achieved partial response (PR). Twenty-one patients (21/39, 53.8{\%}) had early radiological response on Day 14. The early radiological response rate in patients with PR was 72.4{\%} (21/29). Only eight patients without a PR on early CT still ended with PR. Among the 29 patients with PR, the PFS (8.1 months) and OS (18.3 months) of the 21 patients with early CT response were shorter than those of the 8 patients without early CT response (11.9 and 24.0 months for PFS and OS, respectively). But the survival differences were statistically non-significant. Conclusions: A very high percentage (72.4{\%}, 21/29) of NSCLC patients with EGFR mutations with PR demonstrates early radiological response to EGFR-TKIs, which would advocate early radiological examination for EGFR-TKI therapy in NSCLC patients.",
keywords = "computed tomography scan, epidermal growth factor receptor, non-small cell lung cancer, treatment response, tyrosine kinase inhibitor",
author = "Chang, {John W.C.} and Hou, {Ming Mo} and Hsieh, {Jia Juan} and Cheung, {Yun Chung} and Wang, {Hung Ming} and Chen, {Jen Shi} and Wang, {Cheng Hsu} and Chen, {Chih Hung} and Yeh, {Kun Yun} and Ou, {Li Ying} and Hsieh, {Chia Hsun} and Wu, {Hong Dar Isaac} and Chen, {Ying Tsong} and Chang, {Il Chi} and Huang, {Shiu Feng}",
year = "2015",
month = "5",
day = "1",
doi = "10.4103/2319-4170.138320",
language = "English",
volume = "38",
pages = "221--228",
journal = "Biomedical Journal",
issn = "2319-4170",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations

T2 - A prospective study

AU - Chang, John W.C.

AU - Hou, Ming Mo

AU - Hsieh, Jia Juan

AU - Cheung, Yun Chung

AU - Wang, Hung Ming

AU - Chen, Jen Shi

AU - Wang, Cheng Hsu

AU - Chen, Chih Hung

AU - Yeh, Kun Yun

AU - Ou, Li Ying

AU - Hsieh, Chia Hsun

AU - Wu, Hong Dar Isaac

AU - Chen, Ying Tsong

AU - Chang, Il Chi

AU - Huang, Shiu Feng

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: The time schedules for response evaluation of epidermal growth factor receptor-tyrosine kinase Inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are still ill-defined. Methods: Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Eligible patients were treated with either 250 mg of gefitinib or 150 mg of erlotinib once daily. The early response rate [computed tomography (CT) scan on Day 14], definitive response rate determined on Day 56, progression-free survival (PFS), overall survival (OS), and toxicity profile were assessed prospectively. Results: Thirty-nine patients were enrolled in this study. A total of 29 patients (29/39, 74.4%) achieved partial response (PR). Twenty-one patients (21/39, 53.8%) had early radiological response on Day 14. The early radiological response rate in patients with PR was 72.4% (21/29). Only eight patients without a PR on early CT still ended with PR. Among the 29 patients with PR, the PFS (8.1 months) and OS (18.3 months) of the 21 patients with early CT response were shorter than those of the 8 patients without early CT response (11.9 and 24.0 months for PFS and OS, respectively). But the survival differences were statistically non-significant. Conclusions: A very high percentage (72.4%, 21/29) of NSCLC patients with EGFR mutations with PR demonstrates early radiological response to EGFR-TKIs, which would advocate early radiological examination for EGFR-TKI therapy in NSCLC patients.

AB - Background: The time schedules for response evaluation of epidermal growth factor receptor-tyrosine kinase Inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are still ill-defined. Methods: Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Eligible patients were treated with either 250 mg of gefitinib or 150 mg of erlotinib once daily. The early response rate [computed tomography (CT) scan on Day 14], definitive response rate determined on Day 56, progression-free survival (PFS), overall survival (OS), and toxicity profile were assessed prospectively. Results: Thirty-nine patients were enrolled in this study. A total of 29 patients (29/39, 74.4%) achieved partial response (PR). Twenty-one patients (21/39, 53.8%) had early radiological response on Day 14. The early radiological response rate in patients with PR was 72.4% (21/29). Only eight patients without a PR on early CT still ended with PR. Among the 29 patients with PR, the PFS (8.1 months) and OS (18.3 months) of the 21 patients with early CT response were shorter than those of the 8 patients without early CT response (11.9 and 24.0 months for PFS and OS, respectively). But the survival differences were statistically non-significant. Conclusions: A very high percentage (72.4%, 21/29) of NSCLC patients with EGFR mutations with PR demonstrates early radiological response to EGFR-TKIs, which would advocate early radiological examination for EGFR-TKI therapy in NSCLC patients.

KW - computed tomography scan

KW - epidermal growth factor receptor

KW - non-small cell lung cancer

KW - treatment response

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84933513414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933513414&partnerID=8YFLogxK

U2 - 10.4103/2319-4170.138320

DO - 10.4103/2319-4170.138320

M3 - Article

C2 - 25179728

AN - SCOPUS:84933513414

VL - 38

SP - 221

EP - 228

JO - Biomedical Journal

JF - Biomedical Journal

SN - 2319-4170

IS - 3

ER -